EXPERIENCE

Dr. Stensland has presented his work to audiences at international scientific conferences, health insurance companies, and governmental healthcare agencies.  Outcomes research can be appropriate for a wide variety of audiences.  His research has been published in a wide range of both clinical and economic scholarly journals ranging from JAMA to The American Journal of Managed Care. 

Publications

Donohue, J. F., Bollu, V. K., Stull, D. E., Nelson, L. M., Valerie SL Williams, Michael D Stensland, & Nicola A Hanania. (in press). Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial. International Journal of Chronic Obstructive Pulmonary Disease.

Amin, A., Bollu, V. K., Stensland, M. D., Netzer, L., & Ganapathy, V. (in press). Treatment patterns for patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease. American Journal of Health-System Pharmacy.

Ganapathy, V., & Stensland, M. D. (2017). Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol. International Journal of Chronic Obstructive Pulmonary Disease, 12, 1793–1801.

Donohue, J. F., Ganapathy, V., Bollu, V., Stensland, M. D., & Nelson, L. M. (2017). Health status of patients with moderate to severe COPD after treatment with nebulized arformoterol tartrate or placebo for 1 year. Clinical Therapeutics, 39, 66–74. 1

Montgomery, W., Treuer, T., Ye, W., Xue, H. B., Wu, S. H., Liu, L., Kadziola, Z., Stensland, M.D., Ascher-Svanum, H. (2014). Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine? Neuropsychiatric Disease and Treatment, 10, 1287–1296.

Ye, W., Montgomery, W., Kadziola, Z., Liu, L., Xue, H., Stensland, M. D., & Treuer, T. (2014). Factors associated with early response to olanzapine and clinical and functional outcomes of early responders treated for schizophrenia in the People’s Republic of China. Neuropsychiatric Disease and Treatment, 10, 869–878.

Montgomery, W., Liu, L., Stensland, M. D., Xue, H. B., Treuer, T., & Ascher-Svanum, H. (2013). The personal, societal, and economic burden of schizophrenia in the People’s Republic of China: implications for antipsychotic therapy. ClinicoEconomics and Outcomes Research: CEOR, 5, 407–418.

Haynes, V. S., Zhu, B., Stauffer, V. L., Kinon, B. J., Stensland, M. D., Xu, L., & Ascher-Svanum, H. (2012). Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study. BMC Psychiatry, 12, 222.

Stensland, M., Watson, P. R., & Grazier, K. L. (2012). An examination of costs, charges, and payments for inpatient psychiatric treatment in community hospitals. Psychiatric Services, 63, 666–671.

Ascher-Svanum, H., Stensland, M. D., Peng, X., Faries, D. E., Stauffer, V. L., Osuntokun, O. O., & Kane, J. M. (2011). Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia. Current Medical Research and Opinion, 27, 115–122.

Ivanova, J. I., Birnbaum, H. G., Kidolezi, Y., Subramanian, G., Khan, S. A., & Stensland, M. D. (2010). Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder. Current Medical Research and Opinion, 26, 2475–2484.

Stensland, M. D., Schultz, J. F., & Frytak, J. R. (2010). Depression diagnoses following the identification of bipolar disorder: costly incongruent diagnoses. BMC Psychiatry, 10, 39.

Stensland, M. D., Zhu, B., Ascher-Svanum, H., & Ball, D. E. (2010). Costs associated with attempted suicide among individuals with bipolar disorder. The Journal of Mental Health Policy and Economics, 13, 87–92.

Kashner, T. M., Stensland, M. D., Lind, L., Wicker, A., Rush, A. J., Golden, R. M., & Henley, S. S. (2009). Measuring use and cost of care for patients with mood disorders: the utilization and cost inventory. Medical Care, 47, 184–190.

Stensland, M. D., Ascher-Svanum, H., Lawson, A. H., & Conley, R. R. (2009). Overestimating the prevalence of subtherapeutic dosing of atypical antipsychotics. The Journal of Clinical Psychiatry, 70, 1189-1191.

Yu, A. P., Atanasov, P., Ben-Hamadi, R., Birnbaum, H., Stensland, M. D., & Philips, G. (2009). Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 12, 708–715.

Yu, A. P., Ben-Hamadi, R., Birnbaum, H. G., Atanasov, P., Stensland, M. D., & Philips, G. (2009). Comparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid population. Current Medical Research and Opinion, 25, 755–764.

Stensland, M. D., Schultz, J. F., & Frytak, J. R. (2008). Diagnosis of unipolar depression following initial identification of bipolar disorder: a common and costly misdiagnosis. The Journal of Clinical Psychiatry, 69, 749–758.

Stensland, M. D., Jacobson, J. G., & Nyhuis, A. (2007). Service utilization and associated direct costs for bipolar disorder in 2004: an analysis in managed care. Journal of Affective Disorders, 101, 187–193.

Tunis, S. L., Faries, D. E., Stensland, M. D., Hay, D. P., & Kinon, B. J. (2007). An examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophrenia. Current Medical Research and Opinion, 23, 97–104.

Zhu, B., Kulkarni, P. M., Stensland, M. D., & Ascher-Svanum, H. (2007). Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder. Current Medical Research and Opinion, 23, 2805–2814.

Ascher-Svanum, H., Stensland, M., Zhao, Z., & Kinon, B. J. (2005). Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry, 5, 3.

Ascher-Svanum, H., Stensland, M. D., Kinon, B. J., & Tollefson, G. D. (2005). Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. Journal of Psychopharmacology. 19, 110–117.

Juster, I. A., Stensland, M., Brauer, L., & Thuras, P. (2005). Use of administrative data to identify health plan members with unrecognized bipolar disorder: a retrospective cohort study. The American Journal of Managed Care, 11, 578–584.

Tunis, S. L., Ascher-Svanum, H., Stensland, M., & Kinon, B. J. (2004). Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs. PharmacoEconomics, 22, 1–8.

Ascher-Svanum, H., Zhu, B., Stensland, M. D., & Sterling, K. (2003). Clinical comparability of schizophrenia patients at two public mental health systems. Administration and Policy in Mental Health, 30, 231–245.

Nash, J. M., Lipchik, G. L., Holroyd, K. A., McCool, H., & Stensland, M. (2003). American Headache Society members’ assessment of headache diagnostic criteria. Headache, 43, 2–13.

Holroyd, K. A., O’Donnell, F. J., Stensland, M., Lipchik, G. L., Cordingley, G. E., & Carlson, B. W. (2001). Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination: a randomized controlled trial. JAMA: The Journal of the American Medical Association, 285, 2208–2215.

Holroyd, K. A., Stensland, M., Lipchik, G. L., Hill, K. R., O’Donnell, F. S., & Cordingley, G. (2000). Psychosocial correlates and impact of chronic tension-type headaches. Headache, 40(1), 3–16.

TECHNICAL WRITING

Caroff, S. N., Leong, S. H., Ng-Mak, D., Campbell, E. C., Berkowitz, R. M., Rajagopalan, K., … Loebel, A. (Accepted). Socioeconomic Disparities and Metabolic Risk in Veterans with Serious Mental Illness. Community Mental Health Journal.

Meyer, J. M., Ng-Mak, D. S., Chuang, C.-C., Rajagopalan, K., & Loebel, A. (2017). Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records. Annals of General Psychiatry, 16, 36.

Tohen, M., Ng-Mak, D., Rajagopalan, K., Halpern, R., Chuang, C.-C., & Loebel, A. (2017). Patient characteristics associated with use of lurasidone versus other atypical antipsychotics in patients with bipolar disorder: analysis from a claims database in the United States. The Primary Care Companion for CNS Disorders, 19(3), 0–0.

Ng-Mak, D., Poon, J.-L., Roberts, L., Kleinman, L., Revicki, D. A., & Rajagopalan, K. (2017). Patient preferences for important attributes of bipolar depression treatments: a discrete choice experiment. Patient Preference and Adherence, 12, 35–44.

Correll, C. U., Ng-Mak, D. S., Stafkey-Mailey, D., Farrelly, E., Rajagopalan, K., & Loebel, A. (2017). Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis. Annals of General Psychiatry, 16, 9.

McIntyre, R. S., Ng-Mak, D., Chuang, C. C., Halpern, R., Patel, P. A., Rajagopalan, K., & Loebel, A. (2017). Major depressive disorder with subthreshold hypomanic (mixed) features: A real-world assessment of treatment patterns and economic burden. Journal of Affective Disorders, 210, 332–337.

Ostacher, M., Ng-Mak, D., Patel, P., Ntais, D., Schlueter, M., & Loebel, A. (2017). Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: A systematic review and network meta-analysis. The World Journal of Biological Psychiatry, 1–11.

Hung, Y.N., Kadziola, Z., Brnabic, A. J., Yeh, J.F., Fuh, J.L., Hwang, J.P., & Montgomery, W. (2016). The epidemiology and burden of Alzheimer’s disease in Taiwan utilizing data from the National Health Insurance Research Database. ClinicoEconomics and Outcomes Research: CEOR, 8, 387–395.

Montgomery, W., Kadziola, Z., Ye, W., Xue, H. B., Liu, L., & Treuer, T. (2015). Correlation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine. Neuropsychiatric Disease and Treatment, 11, 177–183.

Kirino, E., Imagawa, H., Goto, T., & Montgomery, W. (2015). Sociodemographics, comorbidities, healthcare utilization and work productivity in Japanese patients with adult ADHD. PloS One, 10, e0132233.

Takahashi, M., Nakahara, N., Fujikoshi, S., & Iyo, M. (2015). Remission, response, and relapse rates in patients with acute schizophrenia treated with olanzapine monotherapy or other atypical antipsychotic monotherapy: 12-month prospective observational study. Pragmatic and Observational Research, 6, 39–46.

Bollu, V., Ernst, F. R., Karafilidis, J., Rajagopalan, K., Robinson, S. B., & Braman, S. S. (2013). Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD. International Journal of Chronic Obstructive Pulmonary Disease, 8, 631–639.

Bollu, V., Ejzykowicz, F., Rajagopalan, K., Karafilidis, J., & Hay, J. W. (2013). Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy. Journal of Medical Economics, 16, 1082–1088.

Bollu, V., Karafilidis, J., Colosia, A., Bennett, L., & Hanania, N. (2013). Comparison of efficacy and safety outcomes in randomized trials of long-acting and short-acting β2-agonists for chronic obstructive pulmonary disease: A review. J Pulmon Resp Med, 3, 1–5.

Otsubo, T., Nakahara, N., Cai, Z., Peng, X., Sugihara, T., Faries, D. E., Flynn, J. A., & Namiki, C. (2012). The comorbidity of depression and pain disorders: A retrospective claims study in Japan. Diagnosis and Treatment [Japanese].

Ye, W., Ascher-Svanum, H., Flynn, J. A., Tanji, Y., & Takahashi, M. (2012). Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan. ClinicoEconomics and Outcomes Research: CEOR, 4, 13–19.

Ye, W., Ascher-Svanum, H., Tanji, Y., Flynn, J. A., Takahashi, M., & Conley, R. (2012). Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis. Neuropsychiatric Disease and Treatment, 259.

Ye, W., Fujikoshi, S., Nakahara, N., Takahashi, M., Ascher-Svanum, H., & Ohmori, T. (2012). Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan. Psychiatry and Clinical Neurosciences, 66, 313–321.

Ye, W., Fujikoshi, S., Nakahara, N., Takahashi, M., Ascher-Svanum, H., & Ohmori, T. (2012). One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study. Pragmatic and Observational Research, 3, 41–49.

Ascher-Svanum, H., Ye, W., Flynn, J., Fujikoshi, S., Nakahara, N., & Takahashi, M. (2011). Clinical and functional outcomes for patients with schizophrenia treated with olanzapine: One-year naturalistic outcomes for inpatients and outpatients in Japan. Clinical Neuropsychopharmacology and Therapeutics, 2, 45–55.

Peng, X., Ascher-Svanum, H., Faries, D., Stauffer, V., Kollack-Walker, S., Kinon, B. J., & Kane, J. (2011). Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy. ClinicoEconomics and Outcomes Research, 79.

Ye, W., Ascher-Svanum, H., Tanji, Y., Flynn, J. A., & Takahashi, M. (2011). Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan. Patient Preference and Adherence, 5, 611–617.

Ye, W., Nakahara, N., Takahashi, M., & Ascher-Svanum, H. (2011). Characteristics of outpatients initiated on olanzapine versus risperidone in the treatment of schizophrenia in Japan: A healthcare database analysis. Clinical Neuropsychopharmacology and Therapeutics, 2, 1–8.

PRESENTATIONS

Stensland, M. D., Bollu, V. K., & Donohue, J. F. (2015, October 24-28). Readmission rates for inpatients with COPD treated with arformoterol or fluticasone/salmeterol. Poster presented at the American College of Chest Physicians, CHEST 2015, Montreal, Canada.

Stensland, M. D., Bollu, V. K., & Donohue, J. F. (2015, October 24-28). Readmission rates for inpatients with COPD treated with arformoterol or tiotropium. Poster presented at the American College of Chest Physicians, CHEST 2015, Montreal, Canada.

Stensland, M. D., Bollu, V. K., & Donohue, J. F. (2015, October 26-29). Cost of hospitalization and length of stay for inpatients with COPD treated with arformoterol or tiotropium. Poster presented at the Academy of Managed Care Pharmacy Meeting, AMCP NEXUS 2015, Orlando, FL.

Bollu, V. K., & Stensland, M. D. (2015, May 15-20). Treatment patterns for inpatients with acute exacerbation of chronic obstructive pulmonary disease. Poster presented at the American Thoracic Society Annual Meeting, Denver, CO.

Netzer, L. M., & Stensland, M. D. (2013, May 18-22). Outpatient treatment patterns for schizophrenia in the United States: A nationally representative analysis using NAMCS and NHAMCS Data. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research – 18th Annual International Meeting, New Orleans, LA.

Stensland, M. D., & Netzer, L. M. (2013, May18-22). Outpatient visits for schizophrenia in the United States: A nationally representative analysis using NAMCS and NHAMCS. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research – 18th Annual International Meeting, New Orleans, LA.

Stensland, M.D., Peng, X., Ascher-Svanum, H., Faries, D., Stauffer, V. L., Osuntokun, O., &  Kane, J. M. (2009, October 8-11). The cost-utility of olanzapine vs. aripiprazole in the treatment of schizophrenia.  Presented at the Institute on Psychiatric Services, New York, NY.   

Stensland, M. D., & Peng, X. (2009, May 16-20).  Continuity of care following hospitalization for bipolar disorder in private payer claims. Presented at the International Society of Pharmacoeconomics and Outcomes Research, Orlando, FL.

Ivanova, J., Birnbaum, H.G. , Kidolezi, Y., Subramanian, G., Stensland, M. D., & Khan, S. A. (2009, May 16-20). Direct cost of patients with treatment resistant and non-treatment resistant major depressive disorder. Presented at the International Society of Pharmacoeconomics and Outcomes Research, Orlando, FL.

Stensland, M. D., & Liu, L. (2008, May 3-7). Cost of psychiatric hospitalizations in the United States in 2006. Paper presented at the International Society of Pharmacoeconomics and Outcomes Research, Toronto, Canada.

Stensland, M. D., Zhu, B., & Shaywitz, J. (2007, October 20-23). Prevalence of treatment resistant depression in usual care in the United States. Paper presented at the ISPOR Annual European Conference, Dublin, Ireland.

Kulkarni, P., Zhu, B., & Stensland, M. (2007, March 28 - April 2). An evaluation of psychiatric diagnoses preceding bipolar diagnosis. Paper presented at the International Congress on Schizophrenia Research, Colorado Springs, CO.

Stensland, M. D., & Nyhuis, A. W. (2006, October 5-8). Concomitant medication use and cost for individuals with bipolar disorder treated with olanzapine or quetiapine. Paper presented at the Institute on Psychiatric Services, New York, NY.

Zhu, B., Kulkarni, P., Stensland, M. D., & Ascher-Svanum, H. (2006, October 5-8). Medication use patterns and costs associated with atypical antipsychotics in the treatment of bipolar disorder. Paper presented at the Institute on Psychiatric Services, New York, NY.

Brown, E., Ketter, T., Houston, J. P., Stensland, M., Orth, P., & Ahl, J. (2006, July 9-13). Olanzapine/fluoxetine combination versus lamotrigine for bipolar I depression: Aggressive behavior and other functional outcomes. Paper presented at the Collegium Internationale Neuro-Psychopharmacologicum (CINP), Chicago, IL.

Stensland, M. D., Nyhuis, A., Jamal, H. H., & Ranjan, R. (2006,  July 9-13). Impairment in quality of life and long-term improvements for individuals with elevated mood from bipolar disorder treated with olanzapine or divalproex in clinical practice. Paper presented at the Collegium Internationale Neuro-Psychopharmacologicum, Chicago, IL.

Zhu, B., Ascher-Svanum, H., Stensland, M. D., Jacobson, J. G., & Ball, D. E. (2006, July 9-13). Costs of suicide attempts in the treatment of bipolar disorder. Paper presented at the Collegium Internationale Neuro-Psychopharmacologicum, Chicago, IL.

Schultz, J. S., Stensland, M. D., & Frytak, J. R. (2006, June 26). Diagnoses of unipolar depression following initial identification of bipolar disorder:  A common and costly incongruent diagnosis. Paper presented at the AcademyHealth Annual Research Meeting, Seattle, WA.

Stensland, M. D., Ranjan, R., Faries, D., Zhu, B., & Houston, J. (2006, May 25). The effectiveness of olanzapine vs. divalproex in clinical practice: A 1-year study of the treatment of mixed, manic and hypomanic episodes of bipolar disorder. Paper presented at the Annual Meeting of the American Psychiatric Association, Toronto, Canada.

Zhu, B., Stensland, M. D., Ascher-Svanum, H., Faries, D. E., Lipkovich, I., & Houston, J. P. (2006, May 25). Predictors of new onset diabetes in the one-year observational study of olanzapine vs. divalproex. Paper presented at the Annual Meeting of the American Psychiatric Association, Toronto, Canada.

Ranjan, R., Stensland, M. D., & Zhu, B. (2005, November 7-10). Common psychiatric comorbidities in patients with bipolar disorder and their families. Paper presented at the US Psychiatric & Mental Health Congress, Las Vegas, NV.

Stensland, M. D., Arciniega, J., & McLaughlin, T. (2005, November 7-10). The effectiveness of aripiprazole relative to other atypical antipsychotics. Paper presented at the US Psychiatric & Mental Health Congress, Las Vegas, NV.

Stensland, M. D., Arciniega, J., & McLaughlin, T. (2005, November 7-10). Hospital outcomes for individuals with schizophrenia treated with atypical antipsychotic monotherapy. Paper presented at the US Psychiatric & Mental Health Congress, Las Vegas, NV.

Stensland, M. D., & Hackworth, J. (2005, November 7-10). Cost of poor adherence to different classes of psychotropic medications used to treat bipolar disorder. Paper presented at the US Psychiatric & Mental Health Congress, Las Vegas, NV.

Stensland, M. D., Schultz, J., & Frytak, J. R. (2005, October 5-9). Depression diagnoses following bipolar diagnoses in claims data:  Incongruent diagnoses related to increased treatment costs. Paper presented at the Institute on Psychiatric Services, San Diego, CA.

Holroyd, K. A., & Stensland, M. D. (2005, June 24). Separate and combined effects of cognitive-behavior therapy and antidepressant medication for chronic tension-type headache: Psychosocial outcomes. Paper presented at the American Headache Society, Philadelphia, PA.

Holroyd, K. A., & Stensland, M.D. (2005, March 30-April 2). Separate and combined effects of CBT and drug therapy: Psychosocial outcomes in the treatment of chronic tension-type headache. Paper presented at the American Pain Society, Boston, MA.

Van Brunt, D. L., Stensland, M. D., & Zachry, W. M. (2004, October 24–27). Outpatient care for bipolar disorder in the united states, 1997-2001. Paper presented at the American College of Clinical Pharmacy, Dallas, Texas.

Stensland, M. D., deLay, N., Ciaglia, M., & Viswanathan, S. (2004, October 9-13). Misdiagnosis of bipolar disorder as unipolar depression: A problematic differential diagnosis in clinical practice. Paper presented at the Eurpoean College of Neuropsychopharmacology, Stockholm, Sweden.

Juster, I. A., & Stensland, M. D. (2004, October 6-10). Improving early recognition of bipolar disorder through use of a computerized algorithmic system on administrative data. Paper presented at the Institute for Psychiatric Services, Atlanta, GA.

deLay, N., Stensland, M., Ciaglia, M., & Viswanathan, S. (2004, June 21). Cost containment opportunities in bipolar. Paper presented at the Collegium Internationale Neuro-Psychopharmacologicum, Paris, France.

Ascher-Svanum, H., Stensland, M. D., Kinon, B. J., & Tollefson, G. D. (2004, May 16-19). Weight gain and improvement in psychopathology during treatment of schizophrenia with antipsychotics and with placebo. Paper presented at the International Society of Pharmacoeconomic and Outcomes Research, Arlington, VA.

deLay, N., Stensland, M., Ciaglia, M., & Viswanathan, S. (2004, May 16-19). The costs of poly-pharmacy, non-drug treatment, number of drugs, and switching for bipolar. Paper presented at the International Society of Pharmacoeconomic and Outcomes Research, Arlington, VA.

deLay, N., Stensland, M., Ciaglia, M., & Viswanathan, S. (2004, May 16-19). Pharmacologic treatment patterns for bipolar disorder. Paper presented at the International Society of Pharmacoeconomics and Outcomes Research, Arlington, VA.

Stensland, M. D., deLay, N., Viswanathan, S., & Ciaglia, M. (2004, May 16-19). When bipolar is being identified: Phase of disorder, provider specialty, facility type, and resource utilization surrounding the initial bipolar diagnosis in clinical practice. Paper presented at the International Society for Pharmacoeconomics and Outcomes Research, Arlington, VA.

deLay, N., Viswanathan, S., Ciaglia, M., Stensland, M., Zhao, Z., & Vedarajan, G. (2004, May 1-6). Medication prescribing patterns for patients with bipolar depression in managed care organizations. Paper presented at the American Psychiatric Association, New York, NY.

deLay, N., Stensland, M., Ciaglia, M., & Viswanathan, S. (2004, April 23). Bipolar treatment patterns and medication costs as compared to schiophrenia and unipolar depression. Paper presented at the College of Psychiatric and Neurologic Pharmacists, Chicago, IL.

Ascher-Svanum, H., Stensland, M. D., Kinon, B. J., Tollefson, G. D., & Smith, R. C. (2003, December 7-11). Weight gain and improvement in psychopathology during treatment of schizophrenia with antipsychotics and with placebo. Paper presented at the American College of Neuropsychopharmacology, San Juan, Puerto Rico.

Tunis, S. L., Hay, D. P., Kinon, B. J., Faries, D. E., & Stensland, M. D. (2003, November 6-8). Medication persistence in schizophrenia treatment:  The impact of antipsychotic agent, therapeutic alliance, and comorbid substance abuse. Paper presented at the 16th Annual U.S. Psychiatric and Mental Health Congress, Orlando, FL.

Ascher-Svanum, H., Stauffer, V., Stensland, M., Nitz, N., Jensik, S., & Kinon, B. J. (2003, May 1-4). The link between weight gain and therapeutic response:  Results from the acute phase of an observational study of olanzapine and ziprasidone. Paper presented at the Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Charleston, South Carolina.

Ascher-Svanum, H., Stensland, M., Kinon, B. J., & Zhao, Z. (2003, March 15). Acute weight gain and improved emotional and functional status in males and females treated with antipsychotics for schizophrenic disorders. Paper presented at the Society for Biological Psychiatry, San Francisco, CA.

Nyhuis, A. W., Stensland, M. D., & Faries, D. E. (2003, March 8-10). Calculating responder days for cost-effectiveness studies. Paper presented at the International Congress on Schizophrenia Research, Colorado Springs, Colorado.